Bicara Therapeutics (BCAX)

• Market cap: $1.31B
• 1 day: -2.01%
• 5 days: -7.96%
• 1 month: -13.64%
• 3 months: 8.11%
• 6 months: 9.89%
• Year to date: 22.1%
• 1 year: 81.32%
• 5 years: -14.57%
• 10 years: -14.57%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Employees: 103